It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Al Jalila Children's Specialty Hospital, based in Dubai, United Arab Emirates, said on Monday that it has signed a deal with Illumina to collaborate on rapid whole-genome sequencing for diagnosing critically ill children.

The overall overseas revenue of listed china companies has a three-year CAGR of more than 25%, and the export volume will rebound significantly in 2022.

ANP Technologies has received Emergency Use Authorization from the US Food and Drug Administration for its NIDS COVID-19 Antigen Home Test, according to the agency said on Thursday.

Innova Medical Group and iXensor said Thursday they have reached a distribution deal covering Europe for the Phronesia Smart Ovulation Test, an Innova-branded assay using iXensor's technology.

The MedTech 100 is a financial index calculated using the Medtech Big 100 companies covered in Medical Design and Outsourcing. The Big 100 is a collection of top medtech companies ranked by annual revenue, R&D spend and employee headcount.

Thermo Fisher Scientific said on Tuesday that it has priced an offering of $1.2 billion of senior notes and an offering of €1.25 billion of senior notes.

Biodesix said on Thursday that it has priced a public offering of 30.5 million shares of its stock at $1.15 apiece for expected gross proceeds of $35.1 million.

Burning Rock Biotech said late Tuesday that its Q3 revenues were up 22 percent year over year, driven by higher volumes of the companies test kits for use in hospitals.

Precision oncology company Novigenix said on Wednesday the successful first closing of a $20 million Series B round.

Ginkgo Bioworks said after the close of the market on Monday that it has raised its full-year 2022 revenue guidance to between $460 million and $480 million, up from previous guidance of between $425 million and $440 million, driven by strength in the firm's biosecurity business.